BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 8996358)

  • 1. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
    Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
    J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
    Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
    J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum chromogranin A in patients with hepatocellular carcinoma.
    Leone N; Pellicano R; Brunello F; Rizzetto M; Ponzetto A
    Clin Exp Med; 2002 Nov; 2(3):119-23. PubMed ID: 12447608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination.
    Fracalanza S; Prayer-Galetti T; Pinto F; Navaglia F; Sacco E; Ciaccia M; Plebani M; Pagano F; Basso D
    Urol Int; 2005; 75(1):57-61. PubMed ID: 16037709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
    Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
    Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas?
    Franke WG; Pinkert J; Runge R; Bredow J; Wunderlich G; Koch R
    Anticancer Res; 2000; 20(6D):5257-60. PubMed ID: 11326706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurements of chromogranin B can serve as a complement to chromogranin A.
    Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
    Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chromogranin A in blood--a useful tumor marker].
    Syversen U; Heide LS; Waldum HL
    Tidsskr Nor Laegeforen; 1997 Oct; 117(26):3810-1. PubMed ID: 9417686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical diagnosis of neuroendocrine GEP tumor.
    Oberg K
    Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion of chromogranin A by peptide-producing endocrine neoplasms.
    O'Connor DT; Deftos LJ
    N Engl J Med; 1986 May; 314(18):1145-51. PubMed ID: 3007986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chromogranin A: a marker of neuroendocrine tumors].
    D'Herbomez M; Gouze V
    Ann Biol Clin (Paris); 2002; 60(6):641-6. PubMed ID: 12446227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum keratinocyte growth factor measurement in patients with prostate cancer.
    Mehta PB; Robson CN; Neal DE; Leung HY
    J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.